The Patent Finder
AB

Antecip Bioventures II LLC

First filing 2012
OverviewNotableFeesChangesFamiliesPatent listSources & methods

272 patents currently held

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in May 2032. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2032
Next term end
14
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Bupropion as a Modulator of Drug Activity US 11,541,021
Cited by 134 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Nov 2033 · Medium confidence
Also notable
Dosage Forms for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease US 9,301,964
Cited by 180 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Ends May 2033 · High confidence
Also notable
Bupropion Dosage Forms with Reduced Food and Alcohol Dosing Effects US 11,717,518
Cited by 29 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2043.
Ends Jan 2043 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Jan 2 to 16, 2027 · next Jan 2
  • 2 fees due Feb 8 to 22, 2027 · next Feb 8
  • 5 fees due Mar 8 to 24, 2027 · next Mar 8
  • 3 fees due Apr 6 to 27, 2027 · next Apr 6
  • 2 fees due May 5, 2027
  • 9 fees due Jun 1 to 24, 2027 · next Jun 1
  • 2 fees due Jul 19 to 30, 2027 · next Jul 19
  • 3 fees due Aug 4 to 23, 2027 · next Aug 4
  • 9 fees due Sep 8 to 24, 2027 · next Sep 8
  • 3 fees due Oct 5 to 30, 2027 · next Oct 5

Which patents, and when each one lapses · Pro

Recent changes

  • 5 of the patents on this record were granted since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,861,648Osteoclast Inhibitors for Knee Conditions
In force
 · Medium confidence
In forceMedium confidence
US 9,895,383Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Complex Regional Pain Syndrome
In force
 · Medium confidence
In forceMedium confidence
US 9,901,589Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Complex Regional Pain Syndrome
In force
 · Medium confidence
In forceMedium confidence
US 10,016,445Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Complex Regional Pain Syndrome
In force
 · Medium confidence
In forceMedium confidence
US 10,016,446Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Paget's Disease of Bone
In force
 · Medium confidence
In forceMedium confidence
US 10,028,908Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Complex Regional Pain Syndrome
In force
 · Medium confidence
In forceMedium confidence
US 10,028,969Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Complex Regional Pain Syndrome
In force
 · Medium confidence
In forceMedium confidence
US 10,034,890Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Complex Regional Pain Syndrome
In force
 · Medium confidence
In forceMedium confidence
US 10,092,581Osteoclast Inhibitors Such as Zoledronic Acid for Low Back Pain Treatment
In force
 · Medium confidence
In forceMedium confidence
US 10,111,837Dosage Forms for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease
In force
 · Medium confidence
In forceMedium confidence
10 of 272 patents shown.
Pro members see all 272.
Pro members: see all 272 patents
Also on record, not counted in the 272: 5 patents in force now held by others · 49 applications pending · 118 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited